复星医药(02196.HK) 公布,控股子公司星盛新辉收到国家药品监督管理局关于同意 XS-03片与FOLFOX 或FOLFIRI和贝伐珠单抗联合用于治疗RAS突变转移性结直肠癌临床试验的批准。该治疗方案中所涉XS-03为集团自主研发的小分子口服PLK1 抑制剂。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-27 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.